Trump Picks Dr. Heidi Overton to Lead the FDA
President Donald Trump has nominated Dr. Heidi Overton, a top White House health policy aide closely aligned with the Make America Healthy Again movement, to serve as Commissioner of the Food and Drug Administration, according to AP News. The announcement, made Wednesday via Truth Social, sets up what is expected to be a contentious Senate confirmation battle over the future direction of the nation’s primary drug and food safety regulator.
Overton, a physician and deputy director of the White House Domestic Policy Council, has served in the administration since January 2025 and has become one of the most influential health policymakers behind the scenes of the MAHA movement. If confirmed, she would replace Dr. Marty Makary, who resigned in May after clashes with the White House over flavored vapes, abortion pill policy, and other issues.
A Loyalist at the Center of Trump’s Health Agenda
Overton’s rise to the FDA nomination reflects the administration’s broader approach to federal health agencies—prioritizing political loyalty and MAHA movement goals over traditional scientific consensus. She stood beside Trump during the August 10 Oval Office event where he signed an executive order to split the MMR vaccine into three separate shots and reduce recommended childhood vaccinations from 18 to 11, as BBC News reported.
Trump praised Overton in his announcement, calling her a “ROCKSTAR” who has worked “directly with Secretary Kennedy, Dr. Oz, and team, to deliver on the MOST TRANSFORMATIVE Health Agenda in History.” Health Secretary Robert F. Kennedy Jr. posted on X that Overton has “exceptional judgment, professionalism, discipline and an unwavering commitment to the American people.”
According to STAT News, Overton has been the top health policymaker behind the scenes of the MAHA movement, helping draft the February 2025 executive order establishing the MAHA Commission and playing a role in changing the childhood vaccine schedule in January 2026.
Third Choice for a Troubled Agency
Overton was Trump’s third choice for the position. Acting FDA Commissioner Kyle Diamantas declined the job, citing personal reservations including his young children, and former Rep. Brad Wenstrup (R-Ohio) also declined, as NBC News reported.
The FDA has experienced significant turmoil during Trump’s second term. Widespread job cuts and staffing issues have plagued the agency, and several senior officials have departed, including Dr. Vinay Prasad, the vaccine and biotech chief, and Dr. Tracy Beth Hoeg, who was replaced as acting drug center director. The agency at one point refused to review Moderna’s mRNA flu shot before backtracking a week later.
Industry leaders are cautiously hopeful that Overton could bring stability, though concerns remain. “The interim acting guy seems to have stabilized the agency after, let’s be generous and say, a rocky period with the prior group,” Les Funtleyder, a health investor at E Squared Capital Management, told C&EN. “The concern, I guess, would be the backsliding to what we had prior to the interim, where it seemed like political considerations were more important than scientific.”
Abortion and Vaccine Policy at the Forefront
Overton is a vocal opponent of abortion, including medication abortion using mifepristone, and has called for stricter regulation of abortion pills. Mifepristone is used in medication abortions that make up close to two-thirds of US abortions, and medical professionals call it “among the safest medications” ever approved by the FDA.
The Guardian reported that Overton has previously described mifepristone as “teleabortion” and “abortion-on-demand,” arguing that Congress should work to strictly regulate it “to protect women and children.” If confirmed, she would be positioned to roll back FDA rules that made abortion pills more accessible.
Her role in the vaccine executive order has drawn sharp criticism from key senators. Sen. Bill Cassidy (R-La.), chair of the Senate Health, Education, Labor and Pensions (HELP) Committee, expressed “strong concerns” about the nomination, calling her role in the vaccine order “almost disqualifying.”
“Her lack of managerial experience does not prepare her well for leading a large organization that is already dealing with staffing and morale issues,” Cassidy posted on X. “Additionally, Dr. Overton’s active role in last week’s nonsensical vaccine executive order calls into question her commitment to standing up for sound science and protecting children’s health.”
Sen. Patty Murray (D-Wash.) was more blunt, calling Overton a “far-right, anti-abortion extremist who has no business leading the FDA.” Republicans hold a one-member majority on the HELP Committee, which must advance the nomination to the full Senate.
An Agency Under Pressure
The next FDA commissioner will inherit a daunting set of challenges. The agency is investigating a cyclospora outbreak linked to tainted iceberg lettuce that has sickened thousands, as well as a multistate salmonella outbreak linked to jalapeño peppers. It is also conducting an ongoing review of widely used antidepressants, including whether they may increase autism risk when used during pregnancy, and is working with the White House to finalize a definition of ultraprocessed foods.
Overton would also face decisions on peptide regulation, following a Kennedy-selected advisory panel’s recommendation to ease access to several peptides popular with wellness influencers, and on e-cigarette and nicotine pouch regulation. The biotech industry has complained about rejections or reversals of drugs for rare diseases, and several FDA deputies have exited the agency.
Some MAHA activists are skeptical of Overton, accusing her of being too moderate or corporate-friendly. Kelly Ryerson, an activist critical of pesticides known as “Glyphosate Girl,” told AP that Overton parroted pesticide manufacturer Bayer’s talking points at a MAHA roundtable in April. “I was stunned by the blatant, undisguised corruption,” Ryerson said.
What’s Next
Overton’s nomination now heads to the Senate HELP Committee, where her confirmation prospects remain uncertain. Cassidy’s “almost disqualifying” comment suggests a difficult path, though Republicans could potentially override his concerns if the White House applies pressure. Democrats, led by Murray, have already signaled they will vote no.
If confirmed, Overton would take the helm of an agency at a crossroads—balancing Trump’s priorities of faster cures and lower drug prices, the anti-regulatory interests of traditional Republicans, and the anti-corporate posture of Kennedy’s MAHA movement. The outcome of her confirmation will signal whether the administration’s approach to federal health agencies will continue or face new constraints in the Senate.
As Al Jazeera noted, the nomination represents a continuation of the Trump administration’s efforts to reshape federal health policy. The Senate’s response will determine whether that vision extends to the FDA’s leadership.